India, Aug. 17 -- EyePoint, Inc. (EYPT) shares plunged Monday after the company reported topline results from the LUGANO Phase 3 trial of DURAVYU in wet age-related macular degeneration (AMD).
The stock is currently trading at $4.585, down $10.165 or 68.92%, on the Nasdaq. It opened at $4.06 after closing the previous session at $14.75. The stock has traded between $3.95 and $19.11 over the past 52 weeks.
The trial's primary endpoint was not achieved in the full dataset, although an ad hoc analysis excluding a 4% asymmetric cohort showed DURAVYU was non-inferior to on-label aflibercept.
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services with permission from RTT News....